glp 1 agonists for obesity Frontiers GLP-1 Agonists Weight Loss Drugs

Since then, the landscape of G-agonists has evolved considerably with respect to both new drugs (triple agonists) and clinical impact beyond obesity per se

Despite the ability of GLP-1s to produce significant weight reduction and related health benefits, challenges such as GI side effects, risk of nutrient inadequacies, loss of muscle and bone mass, high costs, frequent discontinuation, and weight regain limit, the use of these drugs for long-term success in individuals and populations

Combining optimized natural GLP-1 strategies with pharmaceutical precision medicine creates a comprehensive approach to sustainable weight loss

While there is not a lot of research comparing the two side by side, some In a 2021 study, the researchers noted that those who injected semaglutide showed more of a reduction in body weight compared to other people who took other approved weight loss medications, such as phentermine

Individuals are entitled to safe and effective medications, and when this standard fails, legal recourse is available

Centers for Disease Control and Prevention, CDC Extended BMI-for-age Growth Charts, National Center for Health Statistics (2024)